Akisü M.Ruhi Özyürek A.Dorak C.Parlar A.Kültürsay N.2019-10-272019-10-2720010010-01610010-0161https://hdl.handle.net/11454/23207This study was designed to investigate the efficacy and safety of enteral ibuprofen for the treatment of patent ductus arteriosus (PDA) and to compare it with enteral indomethacin. Twenty-three premature infants with gestational ages of less than 35 weeks with echocardiographically confirmed PDA were randomly assigned to receive either enteral indomethacin (3 × 0.2 mg/kg at 12 hour intervals) or enteral ibuprofen (1 × 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later). PDA closed in eight of 11 patients (72%) from the indomethacin group and in 10 of 12 (83%) from the ibuprofen group in the first treatment. Five patients (three from indomethacin group, two from ibuprofen group) required a second treatment with the same drug. Ultimately, PDA closed in nine preterm infants from the indomethacin group (81%) and in 10 preterm infants from the ibuprofen group (83%). Ibuprofen patients had a better urinary output compared with the indomethacin group, an ibuprofen treatment was not associated with significant side effects. As a result, ibuprofen treatment seems to be as efficient as indomethacin in closing PDA in preterm infants, with fewer renal side effects.trinfo:eu-repo/semantics/closedAccessIbuprofenIndomethacinNewbornPatent ductus arteriosusArticle4415660Q4